Search

Displaying results 2051 - 2060 of 3020 in total
  1. Drug

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

    go.drugbank.com/drugs/DB18681
    Experimental

    It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.

  2. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]

  3. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487]

  4. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  5. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  6. Drug

    Resveratrol

    go.drugbank.com/drugs/DB02709
    Investigational

    It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers.

    Synonyms: (E)-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
  7. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  8. Drug

    Choline alfoscerate

    go.drugbank.com/drugs/DB04660
    Investigational

    (From Stedman, 26th ed) It counteracts the effects of urea on enzymes and other macromolecules. [PubChem]

  9. Drug

    Nitrilotriacetic acid

    go.drugbank.com/drugs/DB03040
    Experimental

    (From Miall's Dictionary of Chemistry, 5th ed.)

  10. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia